​

The global cancer cachexia market has the potential to grow into a multi-billion-dollar industry.

​

Nuforal is designed to address a critical unmet need for cancer patients in severe physical and mental states, often unable to undergo essential medical treatments. Such a groundbreaking solution will undoubtedly be embraced by the medical ecosystem, including pharmaceutical companies, hospitals, insurers, and health-tech innovators.

​

MetaboCure represents an exceptional investment opportunity - join us in our pioneering journey from the very beginning!

​

Even if Nuforal initially targets only a subset of the global cancer cachexia market - patients with specific cancer types, while MetaboCure will first address pancreatic cancer cachexia - our conservative projections estimate revenues in the billions within three years of launch.

​

Moreover, significant savings on hospitalization costs are anticipated in the U.S. market due to Nuforal's usage. Current direct medical costs for cancer treatment encompass hospital stays, surgeries, chemotherapy, radiation therapy, and other therapies:​

• According to the Journal of Oncology Practice, the average annual treatment cost for pancreatic cancer in the U.S. is approximately $62,130, excluding surgical expenses.

• Surgical procedures for pancreatic cancer can range between $29,000 and $175,000, depending on complexity.

• Advanced therapies, such as immunotherapy and gene therapy, may cost hundreds of thousands of dollars annually per patient.

​

Nuforal's innovative approach has the potential to dramatically reduce these financial burdens while profoundly improving patients' quality of life and survival rates. Our pricing strategy will ensure affordability, making this life-changing treatment accessible to those who need it most.

Because life is priceless, MetaboCure is committed to delivering real hope to patients and reshaping the future of cancer care.